Literature DB >> 26413230

Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failure.

Katie A McCrink1, Ava Brill1, Anastasios Lymperopoulos1.   

Abstract

Heart failure (HF), the number one cause of death in the western world, is caused by the insufficient performance of the heart leading to tissue underperfusion in response to an injury or insult. It comprises complex interactions between important neurohormonal mechanisms that try but ultimately fail to sustain cardiac output. The most prominent such mechanism is the sympathetic (adrenergic) nervous system (SNS), whose activity and outflow are greatly elevated in HF. SNS hyperactivity confers significant toxicity to the failing heart and markedly increases HF morbidity and mortality via excessive activation of adrenergic receptors, which are G protein-coupled receptors. Thus, ligand binding induces their coupling to heterotrimeric G proteins that transduce intracellular signals. G protein signaling is turned-off by the agonist-bound receptor phosphorylation courtesy of G protein-coupled receptor kinases (GRKs), followed by βarrestin binding, which prevents the GRK-phosphorylated receptor from further interaction with the G proteins and simultaneously leads it inside the cell (receptor sequestration). Recent evidence indicates that adrenal GRK2 and βarrestins can regulate adrenal catecholamine secretion, thereby modulating SNS activity in HF. The present review gives an account of all these studies on adrenal GRKs and βarrestins in HF and discusses the exciting new therapeutic possibilities for chronic HF offered by targeting these proteins pharmacologically.

Entities:  

Keywords:  Adrenal medulla; Adrenergic receptor; G protein-coupled receptor; G protein-coupled receptor kinase; Heart failure; Sympathetic nervous system

Year:  2015        PMID: 26413230      PMCID: PMC4577680          DOI: 10.4330/wjc.v7.i9.539

Source DB:  PubMed          Journal:  World J Cardiol


  45 in total

Review 1.  Regulation of G protein-coupled receptor kinases.

Authors:  R B Penn; A N Pronin; J L Benovic
Journal:  Trends Cardiovasc Med       Date:  2000-02       Impact factor: 6.677

2.  Ischemic emergency?: endothelial cells have their own "adrenaline shot" at hand.

Authors:  Anastasios Lymperopoulos
Journal:  Hypertension       Date:  2012-06-04       Impact factor: 10.190

3.  Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission.

Authors:  L Hein; J D Altman; B K Kobilka
Journal:  Nature       Date:  1999-11-11       Impact factor: 49.962

4.  Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Erhe Gao; Steven N Ebert; Gerald W Dorn; Walter J Koch
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

5.  Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Carmela Zincarelli; Jihee Kim; Walter J Koch
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

Review 6.  GRK2 inhibition in heart failure: something old, something new.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes.

Authors:  Melanie Philipp; Lutz Hein
Journal:  Pharmacol Ther       Date:  2004-01       Impact factor: 12.310

Review 8.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

9.  Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart.

Authors:  Kirsten Leineweber; Thekla Wangemann; Christine Giessler; Heike Bruck; Stefan Dhein; Martin Kostelka; Friedrich Wilhelm Mohr; Rolf Edgar Silber; Otto Erich Brodde
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  3 in total

1.  GTPγS Assay for Measuring Agonist-Induced Desensitization of Two Human Polymorphic Alpha2B-Adrenoceptor Variants.

Authors:  Jordana I Borges; Alexandra M Carbone; Natalie Cora; Anastasiya Sizova; Anastasios Lymperopoulos
Journal:  Methods Mol Biol       Date:  2022

2.  GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone.

Authors:  Celina M Pollard; Malka S Suster; Natalie Cora; Alexandra M Carbone; Anastasios Lymperopoulos
Journal:  World J Cardiol       Date:  2022-04-26

3.  Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy.

Authors:  Anastasios Lymperopoulos; Beatrix Aukszi
Journal:  World J Cardiol       Date:  2017-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.